METTL3 and myeloid leukemia: Corresponded to the detected abnormal m6A modification of MYC mRNA in many cancers, including myeloid leukemia 15, bladder cancer 16, and GBM 29, aberrant MYC expression was also caused by METTL3-mediated m6A modification in PCa.